Weinshenker et al [6] have reported the importance of serum AQP4-IgG in the disease progression of NMO patients, and suggested that immunosuppressive treatment may lessen the chance of a second or subsequent attack of transverse myelitis even before the clinical criteria for NMO are satisfied. Here, AQP4 is linked to transverse myelitis.